PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Ocumension Therapeutics  (1477.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINKYG674111011
SectorHealthcare
IndustryBiotechnology

Highlights

Market CapHK$4.12B
Revenue (TTM)HK$246.37M
Gross Profit (TTM)HK$102.92M
EBITDA (TTM)-HK$375.05M
Year RangeHK$4.51 - HK$10.40
Target PriceHK$8.59

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Ocumension Therapeutics 

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in Ocumension Therapeutics , comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-40.00%-30.00%-20.00%-10.00%0.00%10.00%20.00%30.00%NovemberDecember2024FebruaryMarchApril
-17.84%
21.29%
1477.HK (Ocumension Therapeutics )
Benchmark (^GSPC)

S&P 500

Returns By Period

Ocumension Therapeutics  had a return of -9.73% year-to-date (YTD) and -32.63% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-9.73%6.33%
1 month1.17%-2.81%
6 months-17.85%21.13%
1 year-32.63%24.56%
5 years (annualized)N/A11.55%
10 years (annualized)N/A10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-24.85%3.39%11.37%
2023-7.38%0.65%-11.30%-2.20%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 1477.HK is 15, indicating that it is in the bottom 15% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of 1477.HK is 1515
Ocumension Therapeutics (1477.HK)
The Sharpe Ratio Rank of 1477.HK is 88Sharpe Ratio Rank
The Sortino Ratio Rank of 1477.HK is 1010Sortino Ratio Rank
The Omega Ratio Rank of 1477.HK is 1313Omega Ratio Rank
The Calmar Ratio Rank of 1477.HK is 2525Calmar Ratio Rank
The Martin Ratio Rank of 1477.HK is 1919Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Ocumension Therapeutics  (1477.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


1477.HK
Sharpe ratio
The chart of Sharpe ratio for 1477.HK, currently valued at -0.91, compared to the broader market-2.00-1.000.001.002.003.00-0.91
Sortino ratio
The chart of Sortino ratio for 1477.HK, currently valued at -1.28, compared to the broader market-4.00-2.000.002.004.006.00-1.28
Omega ratio
The chart of Omega ratio for 1477.HK, currently valued at 0.86, compared to the broader market0.501.001.500.86
Calmar ratio
The chart of Calmar ratio for 1477.HK, currently valued at -0.41, compared to the broader market0.001.002.003.004.005.006.00-0.41
Martin ratio
The chart of Martin ratio for 1477.HK, currently valued at -1.17, compared to the broader market0.0010.0020.0030.00-1.17
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.91, compared to the broader market-2.00-1.000.001.002.003.001.91
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.77, compared to the broader market-4.00-2.000.002.004.006.002.77
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.46, compared to the broader market0.001.002.003.004.005.006.001.46
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.61, compared to the broader market0.0010.0020.0030.007.61

Sharpe Ratio

The current Ocumension Therapeutics  Sharpe ratio is -0.91. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.91
1.90
1477.HK (Ocumension Therapeutics )
Benchmark (^GSPC)

Dividends

Dividend History


Ocumension Therapeutics  doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-83.70%
-3.41%
1477.HK (Ocumension Therapeutics )
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Ocumension Therapeutics . A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ocumension Therapeutics  was 87.24%, occurring on Feb 5, 2024. The portfolio has not yet recovered.

The current Ocumension Therapeutics  drawdown is 83.70%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-87.24%Jul 13, 2020881Feb 5, 2024

Volatility

Volatility Chart

The current Ocumension Therapeutics  volatility is 9.57%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%NovemberDecember2024FebruaryMarchApril
9.57%
3.62%
1477.HK (Ocumension Therapeutics )
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Ocumension Therapeutics  over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items